INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2012

Intravenous ascorbic acid with gemcitabine and erlotinib showed acceptable safety in pancreatic cancer

In a dose-escalation trial of 14 patients with stage IV pancreatic cancer, nine completed an eight-week cycle of thrice-weekly intravenous ascorbic acid alongside gemcitabine and erlotinib. The trial recorded 15 non-serious and eight serious adverse events, all deemed related to disease progression or chemotherapy. RECIST evaluation showed stable disease in seven participants and progressive disease in two, indicating no added toxicity from ascorbic acid.

Study type
Phase I dose-escalation trial
Who was studied
14 patients with metastatic stage IV pancreatic cancer
What was measured
Safety, adverse events, and disease response

THE PAPER

Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.

Monti DA, Mitchell E, Bazzan AJ, Littman S, Zabrecky G, Yeo CJ, Pillai MV, Newberg AB, Deshmukh S, Levine M. PLoS One, 2012.

PubMed 22272248 ↗DOI 10.1371/journal.pone.0029794 ↗

CancerNutrients & adequacy

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.